objective To recommend a cost-effective approach for the management of acute male urethritis in the developing world, based on the findings of a theoretical study. methods A model was developed to assess the cost-effectiveness of three urethritis management strategies in a theoretical cohort of 1000 men with urethral syndrome. (1) All patients were treated with cefixime and doxycycline for gonococcal urethritis (GU) and nongonococcal urethritis (NGU), respectively, as recommended by WHO. (2) All patients were treated with doxycycline for NGU; treatment with cefixime was based on the result of direct microscopy of a urethral smear. (3) All patients were treated with cotrimoxazole or kanamycin for GU and doxycycline for NGU. Cefixime was kept for patients not responding to the first GU treatment. Strategy costs included consultations, laboratory diagnosis (where applicable) and drugs. The outcome was the rate of patients cured of urethritis. Cost-effectiveness was measured in terms of cost per cured urethritis. results Strategy costs in our model depended largely on drug costs. The first strategy was confirmed as the most effective but also the most expensive approach. Cefixime should cost no more than US$ 1.5 for the strategy to be the most cost-effective. The second strategy saved money and drugs but proved a valuable alternative only when laboratory performance was optimal. The third strategy with cotrimoxazole was the least expensive but a low follow-up visit rate, poor treatment compliance or lower drug efficacy limited effectiveness. Maximizing compliance by replacing cotrimoxazole with single-dose kanamycin had the single greatest impact on the effectiveness of the third strategy. conclusion Our model suggested that a cost-effective approach would be to treat gonorrhoea with a single-dose antibiotic selected from locally available products that cost no more than US$ 1.5. keywords urethritis, treatment, cost-effectiveness, syndromic approach correspondence Marie
Introduction
Urethritis in men is primarily caused by gonococcal and chlamydial infection . It is well known that prompt and effective treatment of urethritis not only prevents complications and sequelae, but also reduces the risk of HIV transmission (Grosskurth et al. 1995; Holmes et al. 1999) . Syndromic management of urethritis following WHO guidelines recommends concurrent antibiotic therapy for gonococcal and chlamydial infection (WHO 1994) . The treatment of gonococcal urethritis used to be straightforward. However, gonococcal resistance to several antibiotics in different parts of the world has made treatment recommendations for gonococcal infection somewhat more complicated. At present there is no single drug for the treatment of gonorrhoea in the developing world that combines efficacy and low price. Cefixime, ceftriaxone, and spectinomycin are recommended by WHO as first-line drugs for the treatment of gonococcal urethritis, because they remain highly efficacious all over the world (Moran & Levine 1995) . However, their main drawback is their high cost. Ciprofloxacin, also recommended by WHO, has become cheaper in some countries, but resistance in South and Southeast Asia means that it can no longer be universally recommended (WHO 1997; Bhalla et al. 1998; Ng et al. 1998; Tapsall et al. 1998; Bhuiyan et al. 1999; Klausner et al. 1999 ). Kanamycin and above all cotrimoxazole are still widely used in Africa where they remain efficacious and are considerably less expensive. Rather than readily endorsing the recommendation for the most efficacious (and expensive) drugs, public health professionals in the developing world may want to identify the most cost-effective approach towards treatment of gonococcal infection.
Basically, STD programme managers face three options for the treatment of gonococcal urethritis, depending on their priorities. The first option focuses on treatment efficacy, with patients being systematically administered the most efficacious antibiotic. It is the gold standard 1 in terms of drug efficacy. A second option aims for diagnosis specificity and drug saving, with gonococcal infection first confirmed by direct microscopy before treatment. The third option sets the priority on financial accessibility, by having gonococcal infection treated in the first place with an inexpensive drug. The debate between defenders of each management strategy has usually focused either on pharmaceutical efficacy or financial accessibility rather than cost-effectiveness. Our objective was to assess the costeffectiveness of the three options by means of a simple model.
Materials and methods

The three management strategies
The first strategy in our model, which focused on treatment efficacy, had all male patients treated for gonococcal infection with a single oral dose of 400 mg cefixime. Ceftriaxone and spectinomycin, the other first-choice drugs according to WHO, require intramuscular administration and are usually even more expensive than cefixime (Management Sciences for Health 1999). The second strategy, focusing on specificity, had patients treated with cefixime depending on the presence of intracellular diplococci on a Gram-stained urethral smear. The third strategy, focusing on financial accessibility, had all subjects treated with cotrimoxazole, 10 tablets of 480 mg daily for 3 days or kanamycin 2 g IM stat, following WHO's recommendations (WHO 1991) . Cefixime was kept for those who failed to respond to first-line treatment. Our model also had all subjects systematically treated for nongonococcal urethritis with doxycycline 100 mg bd. for 7 days, following WHO's recommendation (WHO 1994) . While the first strategy was the gold standard, the other two were potential alternatives to be evaluated.
The model
Decision trees were developed to model the management of gonococcal and nongonococcal infection following the three strategies in a hypothetical cohort of 1000 male patients with symptoms and/or signs of urethritis (Figures 1,2,3) . The model was kept simple by leaving aside the costs associated with complications in men and in their female partners. Transmission and complication rates were indeed assumed to remain constant in the absence of any intervention. Two additional assumptions were made to limit the complexity of the decision trees. First, patients not infected with gonorrhoea were considered correctly diagnosed by microscopy (i.e. no false positives) and therefore not treated. Secondly, patients not compliant with multidose antibiotic therapy, be it for gonococcal or chlamydial infection, were considered lost and not cured.
The cost of each strategy included consultations, microscopic examination where applicable, and antibiotics for gonococcal and chlamydial infection. The costs of 1 'Gold standard' refers to the generally preferred strategy. consultation and laboratory were based on government sector's salaries and workload in several of the poorest countries in sub-Saharan Africa, Latin America and Asia 2 .
Healthcare provider and laboratory technician's salaries were set at US$ 75 and 100, respectively, for 460 consultations per month. cefixime was provided by an international nonprofit drug distributor in the Netherlands. Drug costs were increased by 30% to include transport and handling. Thus the values used in the model were US$ 4.0, 0.9, 0.7 and 0.6, respectively, for a full course of cefixime, kanamycin, cotrimoxazole and doxycycline. The outcome indicator for each strategy was the rate of patients cured of urethritis. The cost per cured urethritis was obtained by dividing the management cost for 1000 patients by the number of cured patients.
Rates and sensitivity analysis Table 1 lists the rates ascribed to some of the variables in the model. These were found in the published literature. The follow-up visit rate was estimated by Delphi survey performed for this study. Factors likely to vary widely across countries or types of setting, such as follow-up visit rate, laboratory performance and antimicrobial resistance were submitted to a sensitivity analysis to assess their impact on the model.
Results
Baseline performance
The baseline performance of the three strategies is shown in Table 2 . Strategy costs depended largely on the cost of drugs. The gold standard strategy yielded the highest outcome at the highest cost. Following our model the total cost of the strategy was US$ 4800 to effectively treat 87% of the 810 infected patients, or US$ 6.8 per cured urethritis. The 105 subjects (13%) not cured were those who had 'failed' to comply with their doxycycline treatment. Strategy 2 was nearly as effective when laboratory performance was optimal. Despite the additional cost of microscopic examination, limiting the use of cefixime resulted in a total cost of US$ 4000 to cure 85% of infected patients. Strategy 3 was the least expensive option, with a total cost of US$ 1,700, but the rate of cured patients did not exceed 64%. Table 3 shows the influence of changing some of the variables on the costeffectiveness of strategies 2 and 3. 
Influence of laboratory performance on cost-effectiveness
The performance of strategy 2 clearly depended on the quality of microscopic examination. Both the effectiveness and total cost decreased, though not markedly, when the sensitivity and specificity were arbitrarily set at 80% and 85%, then 60% and 70%, respectively. However, the cost per individual patient increased since the number of cured patients dropped faster than the total cost.
Influence of the follow-up visit rate
Keeping the gold standard in mind, we first modified the follow-up visit rate in strategy 3 to observe its effect on costeffectiveness. Even after almost tripling the follow-up visit rate, the effectiveness only increased from 64% to 72%. While the total cost rose as a consequence of the greater number of patients treated with cefixime, the cost per cured urethritis was only marginally increased.
Influence of drug efficacy
When cotrimoxazole efficacy was maximized (the other variables being unchanged), 599 patients (74%) were cured at an individual cost of US$ 2.5. In the 100%-efficacy scenario, the effectiveness was basically limited by the 74% compliance with the multidrug regimen. We also looked at the consequence of replacing cotrimoxazole with single-dose kanamycin. At a 70% efficacy kanamycin cured 74% of the cohort at a cost of US$ 3.2 per cured patient. As the efficacy of the drug went up, the percentage of cured patients went up and the costs went down. With kanamycin efficacy at 100%, strategy 3 matched strategy 1 in terms of efficacy but at one third of the cost.
Our findings remained unchanged even after raising the unit costs for consultation from US$ 0.16 to 0.48, and for laboratory testing from US$ 1.17 to 1.66. This actually meant tripling labour costs or dividing workload by three. Only when labour costs were multiplied by six did strategy 1 become less expensive than strategy 2, as labour costs associated with strategy 2 surpassed drug savings. Likewise, our findings were unaffected by modifying the rates of gonococcal, chlamydial or mixed infection in the model. Finally, we calculated the price cefixime should ideally not exceed in order to have strategy 1 comparing favourably in terms of cost with the least expensive strategy. At US$ 1.5 per cefixime treatment, the total cost of the first strategy dropped to the baseline cost of the third strategy, i.e. US$ 2,300, or slightly less than US$ 3.3 per cured urethritis.
Discussion
In short, the gold standard strategy was, as expected, both the most effective and the most expensive approach. Strategy 2 matched the gold standard only when laboratory performance was optimal. Falling laboratory performance led to effectiveness falling similarly. Strategy 3 using cotrimoxazole was the least expensive, but was limited by treatment compliance even at the highest drug efficacy. With kanamycin, the effectiveness of strategy 3 depended mainly on drug efficacy. At 100% drug efficacy, it matched the gold standard in terms of effectiveness, at a much lower cost.
These findings confirm what most public health decisionmakers already knew intuitively, but they pointed to a few additional facts. The gold standard strategy is expensive when third-generation cephalosporins have to be recommended. At US$ 4 per treatment with cefixime, drug costs dwarf labour costs. In a country like Cambodia, a reasonable estimate of the cost of procuring drugs for the syndromic management of STDs at primary encounter level nationwide amounted to nearly US$ 3 million per year, with cefixime representing most of it. The national government is obviously unable to face such an enormous cost. Since patients are equally unable to afford treatment, the best drug for the treatment of gonococcal infection remains managed to obtain them at around US$ 1.5, strategy 1 with quinolones is definitely the preferred option. Strategy 2 seems to offer an attractive alternative to the gold standard especially where labour costs (and thus the cost of laboratory work) are much lower than imported drugs. However, our model showed that this option is valid only when laboratory performance is optimal. Its advantages become marginal when the quality of laboratory work falls below this level.
When increasing the follow-up visit rate in Strategy 3 we were surprised that its impact was so limited. However, our model revealed that only 90 patients with gonorrhoea and 36 with mixed infection were likely to return for a follow-up visit. Thus increasing the follow-up visit rate from 34 to 90% added only 71 subjects to the total number of cured patients. Our model clearly suggested that efforts to bring patients back to the consultation would have limited benefit. Improving the efficacy of cotrimoxazole in Strategy 3 resulted in increased effectiveness and lower costs. However, our model highlighted the importance of treatment compliance. Even at maximum efficacy, the total rate of cured patients with cotrimoxazole as the first line drug (599) was just under the rate obtained with a single administration drug such as kanamycin at 70% efficacy (601). Our model suggested that the multiple-dose cotrimoxazole regimen, however efficacious and inexpensive, should no longer be recommended when there is a single administration alternative that does not cost more than US$ 1.5.
Which single-dose products could be used to treat gonococcal infection at an acceptable cost in the developing world? Unfortunately there is no single inexpensive drug. Since gonococcal resistance to antibiotics varies extensively across countries, local assessment of drug efficacy has become mandatory and options vary. For example, the single administration of amoxycillin and clavulanic acid is currently the preferred option in Kenya. Gentamycin is recommended in Malawi and kanamycin in Zimbabwe.
Our theoretical exercise has limitations. Only a few variables were considered in the model. In order to keep it simple, patients not compliant with multiple-dose drug regimens (cotrimoxazole or doxycycline) were considered lost and not cured. The rate of transmission of infection to female partners as well as the rate of complications were deemed constant and not taken into account. Costs included only drugs, consultations and microscopic examination where applicable. Extra costs associated with improving the follow-up visit rate or with monitoring gonococcal antimicrobial resistance were not considered. Low labour costs are representative of many countries in the developing world, but do not necessarily apply worldwide. Finally the issue of intramuscular administration vs. oral intake was not considered.
Nevertheless, by translating concepts into numbers our model emphasized the advantages and limitations of the three strategies, and suggested the following two conclusions. First, the simplest and most cost-effective approach for public health decision-makers might be to negotiate the purchase of WHO's recommended drugs at around US$ 1.5 per treatment. Alternatively, they might try to identify an efficacious single-dose product from among inexpensive antibiotics, based on local gonococcal resistance findings. Secondly, cotrimoxazole should be abandoned for the treatment of gonococcal infection, especially if there is a single administration alternative that does not cost more than US$ 1.5.
